Evidence map›Paper›PMID 40563010›Full record

ArticleNature structural & molecular biology2025

The PURB-HOTAIR complex regulates p53-dependent promoter-specific transcriptional activation.

Zhangchuan Xia, Ning Kon, Zhenyi Su, Jingjie Yi, Xu Hua, Hui Zhou, Zhiguo Zhang, Wei Gu

Abstract read
In one paragraph

Article in Nature structural & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhangchuan XiaInstitute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-1176-0027
Ning KonInstitute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Zhenyi SuInstitute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Jingjie YiInstitute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Xu HuaInstitute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Hui ZhouInstitute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Zhiguo ZhangInstitute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-9451-2685
Wei GuInstitute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA. wg8@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-1480-2368

Funding

p53-mediated metabolic regulation in tumor suppressionR35CA253059 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Wei Gu · 2021 to 2026
$5.3M
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylationR01CA258390 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Wei Gu · 2022 to 2026
$2.3M
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapyR01CA254970 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA254970NCI NIH HHS R01 CA258390NCI NIH HHS R35 CA253059
6 · The paper itself

Abstract

p53 executes its diverse functions through different transcriptional targets but the precise mechanism of promoter-specific regulation by p53 remains largely unknown. Through biochemical purification, we identify purine-rich element binding protein B (PURB), a dual DNA/RNA-binding protein, which acts as a transcriptional corepressor for p53 in a manner dependent on p53 acetylation status. PURB is overexpressed in human cancers, and its knockdown induces p53-dependent activation of p21 but has no effect on other major promoters such as PUMA and MDM2. In contrast to other p53 corepressors, PURB can recognize a unique DNA element at the p21 promoter, with the loss of this element not affecting p53-mediated transactivation but abrogating the ability of p53 to recruit PURB to the p21 promoter for repression. Mechanistically, PURB requires its sequence-specific binding with long noncoding RNA (lncRNA) HOX transcript antisense RNA (HOTAIR) to exert its repressive role. In turn, HOTAIR interacts directly with EZH2 and, bridged by the PURB-HOTAIR complex, p53 can recruit the EZH2 histone methyltransferase to target promoters for transcriptional repression. Further analysis of p53 targets reveals several promoters that may serve as targets for PURB binding, suggesting that this mechanism of PURB-dependent promoter-specific regulation may not be limited to p21. These data establish a mode of lncRNA-mediated regulation of p53 transcription in a sequence-specific manner and reveal a previously unanticipated mechanism for acetylation-mediated promoter-specific regulation through a cis-regulatory element recognized by the PURB-HOTAIR complex.

Indexed as

DNA-Binding ProteinsPromoter Regions, GeneticRNA, Long NoncodingTranscriptional ActivationTumor Suppressor Protein p53AcetylationCell Line, TumorCyclin-Dependent Kinase Inhibitor p21Enhancer of Zeste Homolog 2 ProteinHumansCyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanRNA, Long NoncodingTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID40563010
PMCPMC13010994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.